Bioeasy Signs Strategic Agreement with Zhongke Yixiang to Build a Brain-Computer Interface Industrial Ecosystem

Source: Shanghai Securities News · China Securities Network

Shanghai Securities News, China Securities Network (Chen Ming, reporter Yang Ye) reported that the reporter learned fromBiotest BiotechIt is reported that recently, Biotest Biotech and Zhongke Imagery (Nanjing) Technology Co., Ltd. (hereinafter referred to as “Zhongke Imagery”) signed a strategic cooperation framework agreement in Hangzhou. The two parties will engage in in-depth collaboration in areas including the joint development of brain-computer interface (BCI) technologies and in vitro diagnostic reagents, support for medical device registration and market access, and the clinical application and promotion of the BCI industry chain. Biotest Biotech stated that this cooperation marks the extension of its industrial layout into the upstream segment of the BCI supply chain and the field of embodied intelligent interaction applications.

Public information indicates that Zhongke Imagery is a brain-computer interface (BCI) technology enterprise incubated by the Institute of Automation, Chinese Academy of Sciences. The company focuses on the deep integration of “brain-computer interfaces, AI, and embodied intelligence,” aiming to achieve full-chain automation encompassing “decoding of brain intentions, autonomous AI planning, and embodied execution by robotic arms.” In routine animal experiments conducted this April, Zhongke Imagery decoded motor intentions in macaques in just 0.2 seconds, with AI autonomously completing motion planning and grasp execution for both the robotic arm and dexterous hand. Furthermore, Zhongke Imagery has proposed the Brain-Computer Interface Grading System (BCIG) and is currently advancing human clinical trials for BCIG Level 3 brain-computer interfaces.

Reporters learned that prior to this collaboration, Biotest Biotech had led the most recent funding round of Zhongke Imagery through the Biotest Brain-Computer Interface Fund. Currently, Biotest Biotech is actively building an industrial ecosystem for brain-computer interfaces through strategic investments and other avenues.

In May 2025, Biotest Biotech strategically acquired a minority stake in Hangzhou Qingshi Yongjun Medical Equipment Co., Ltd., holding a 5% equity share post-investment. The company’s core founding team hails from the State Key Laboratory of Brain-Machine Intelligence at Zhejiang University and is the first research team in China to achieve therapeutic outcomes for refractory severe depression through precise targeting in implantable Deep Brain Stimulation (DBS).

In January 2026, Biotest Biotech strategically acquired a minority stake in Hangzhou Haoshi Tianhui Technology Co., Ltd., holding a 16% equity share post-investment. The company primarily focuses on diagnosis and adjunctive therapy via non-invasive brain-computer interfaces (BCI). Its independently developed medical-grade non-invasive BCI and mental health assessment devices can complete precise quantitative assessments of emotional disorders, such as depression and anxiety, in as little as 90 seconds.

In March 2026, Biotest Biotech established a special industrial fund for brain-computer interfaces and brain science, with a total size of RMB 200 million. The fund is primarily used to invest in unlisted companies within the domestic and international brain-computer interface and brain science-related industry chains. As a limited partner, Biotest Biotech subscribed to RMB 190 million, accounting for 95% of the fund.

Biotest Biotech stated that, in the future, the company will leverage the expertise and resource advantages of professional investment institutions to accelerate the strategic layout of brain-computer interfaces and promote the integration and sharing of advantageous resources.